Real-world safety of icosapent ethyl: analysis based on spontaneous reports in FAERS database

References

• Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke statistics—2019 update: a report from the American Heart association. Circulation. 2019;139(10):e56–e528. doi: 10.1161/CIR.0000000000000659
   PubMed Web of Science ®Google Scholar
• Roth GA, Johnson C, Abajobir A, et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol. 2017;70(1):1–25. doi: 10.1016/j.jacc.2017.04.052
   PubMed Web of Science ®Google Scholar
• Ganda OP, Bhatt DL, Mason RP, et al. Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia management. J Am Coll Cardiol. 2018;72(3):330–343. doi: 10.1016/j.jacc.2018.04.061
   PubMed Web of Science ®Google Scholar
• Ference BA, Kastelein JJP, Ray KK, et al. Association of triglyceride-lowering LPL variants and LDL-C–lowering LDLR variants with risk of coronary Heart disease. JAMA. 2019;321(4):364. doi: 10.1001/jama.2018.20045
   PubMed Web of Science ®Google Scholar
• Fan W, Philip S, Granowitz C, et al. Hypertriglyceridemia in statin-treated US adults: the national health and nutrition examination survey. J Clin Lipidol. 2019;13(1):100–108. doi: 10.1016/j.jacl.2018.11.008
   PubMed Web of Science ®Google Scholar
• Sumner AE, Cowie CC. Ethnic differences in the ability of triglyceride levels to identify insulin resistance. Atherosclerosis. 2008;196(2):696–703. doi: 10.1016/j.atherosclerosis.2006.12.018
   PubMed Web of Science ®Google Scholar
• Toth PP, Fazio S, Wong ND, et al. Risk of cardiovascular events in patients with hypertriglyceridaemia: a review of real-world evidence. Diab Obes Metab. 2020;22(3):279–289. doi: 10.1111/dom.13921
   PubMed Web of Science ®Google Scholar
• Handelsman Y, Jellinger PS, Guerin CK, et al. Consensus statement by the American association of clinical endocrinologists and American college of endocrinology on the management of dyslipidemia and prevention of cardiovascular disease algorithm – 2020 executive summary. Endocr Pract. 2020;26(10):1196–1224. doi: 10.4158/CS-2020-0490
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11–22. doi: 10.1056/NEJMoa1812792
   PubMed Web of Science ®Google Scholar
• Food and drug administration (FDA). The label of icosapent ethyl [EB/OL]. Dec 2019. [cited 2023 Apr 2]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202057s035lbl.pdf
   Google Scholar
• European Medicines Agency(EMA). Vazkepa: EPAR-Product information [EB/OL]. Mar 2021. [cited 2023 Apr 2] Available from: www.ema.europa.eu/en/documents/product-information/vazkepa-epar-product-information_en.pdf
   Google Scholar
• Visseren F, Mach F, Smulders YM, et al. ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021. 2021;42(34):3227–3337.
   Google Scholar
• Ballantyne CM, Bays HE, Kastelein JJ, et al. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol. 2012;110(7):984–992. doi: 10.1016/j.amjcard.2012.05.031
   PubMed Web of Science ®Google Scholar
• Davis SE, Zabotka L, Desai RJ, et al. Use of electronic Health record data for drug safety signal Identification: a scoping review. Drug Saf. 2023;46(8):725–742. doi: 10.1007/s40264-023-01325-0
   PubMed Web of Science ®Google Scholar
• Gatti M, Antonazzo IC, Diemberger I, et al. Adverse events with sacubitril/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system. Eur J Prev Cardiol. 2021;28(9):983–989. doi: 10.1177/2047487320915663
   PubMed Web of Science ®Google Scholar
• Food and drug administration adverse event reporting system (FAERS). [cited 2023 Apr 25]. Available from: https://fis.fda.gov/extensions/FPD-QDE-FAERS/FPD-QDE-FAERS.html.
   Google Scholar
• European Medicines Agency. Screening for adverse reactions in EudraVigilance. EMA/849944/2016. 2016 [cited 2023 May 2]:p. 3–33. Available from: https://www.ema.europa.eu/en/documents/other/screening-adverse-reactions-eudravigilance_en.pdf
   Google Scholar
• Huang L, Guo T, Zalkikar JN, et al. A review of statistical Methods for safety surveillance. Ther Innov Regul Sci. 2014;48(1):98–108. doi: 10.1177/2168479013514236
   PubMed Web of Science ®Google Scholar
• Shu Y, He X, Wu P, et al. Gastrointestinal adverse events associated with semaglutide: a pharmacovigilance study based on FDA adverse event reporting system. Front Public Health. 2022;10:996179. doi: 10.3389/fpubh.2022.996179
   PubMed Web of Science ®Google Scholar
• Guo H, Wang B, Yuan S, et al. Neurological adverse events associated with Esketamine: a disproportionality analysis for signal detection leveraging the FDA adverse event reporting system. Front Pharmacol. 2022;13:849758. doi: 10.3389/fphar.2022.849758
   PubMed Web of Science ®Google Scholar
• Shu Y, Wang L, Ding Y, et al. Disproportionality analysis of abemaciclib in the FDA adverse event reporting system: a real-world post-marketing pharmacovigilance assessment. Drug Saf. 2023;46(9):881–895. doi: 10.1007/s40264-023-01334-z
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Designated medical event (DME) list. EMA/326038/2020. 2020. [cited 2023 May 3]. Available from: https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/signal-management#designated-medical-events-section
   Google Scholar
• European Medicines Agency. MedDRA important medical event terms list - version 26.0. EMA/135819/2023. 2023. [cited 2023 May 3]. Available from: https://www.ema.europa.eu/en/human-regulatory/research-development/pharmacovigilance/eudravigilance/eudravigilance-system-overview
   Google Scholar
• Fusaroli M, Isgro V, Cutroneo PM, et al. Post-marketing surveillance of CAR-T-Cell therapies: analysis of the FDA adverse event reporting system (FAERS) database. Drug Saf. 2022;45(8):891–908. doi: 10.1007/s40264-022-01194-z
   PubMed Web of Science ®Google Scholar
• Kaku K, Nakayama Y, Yabuuchi J, et al. Safety and effectiveness of empagliflozin in clinical practice as monotherapy or with other glucose-lowering drugs in Japanese patients with type 2 diabetes: subgroup analysis of a 3-year post-marketing surveillance study. Expert Opinion On Drug Safety. 2023;22(9):819–832. doi: 10.1080/14740338.2023.2213477
   PubMed Web of Science ®Google Scholar
• Setyawan J, Azimi N, Strand V, et al. Reporting of thromboembolic events with JAK inhibitors: analysis of the FAERS database 2010–2019. Drug Saf. 2021;44(8):889–897. doi: 10.1007/s40264-021-01082-y
   PubMed Web of Science ®Google Scholar
• Shu Y, Ding Y, Dai B, et al. A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system. Expert Opin Drug Saf. 2022;21(4):563–572. doi: 10.1080/14740338.2022.2016696
   PubMed Web of Science ®Google Scholar
• Mazhar F, Battini V, Gringeri M, et al. The impact of anti-TNFα agents on weight-related changes: new insights from a real-world pharmacovigilance study using the FDA adverse event reporting system (FAERS) database. Expert Opin Biol Ther. 2021;21(9):1281–1290. doi: 10.1080/14712598.2021.1948529
   PubMed Web of Science ®Google Scholar
• Kinoshita S, Hosomi K, Yokoyama S, et al. Time-to-onset analysis of amiodarone-associated thyroid dysfunction. J Clin Pharm Ther. 2020;45(1):65–71. doi: 10.1111/jcpt.13024
   PubMed Web of Science ®Google Scholar
• Cornelius VR, Sauzet O, Evans SJ. A signal detection method to detect adverse drug reactions using a parametric time-to-event model in simulated cohort data. Drug Saf. 2012;35(7):599–610. doi: 10.2165/11599740-000000000-00000
   PubMed Web of Science ®Google Scholar
• Islam N, Cichero E, Rahman S, et al. Novel pulmonary delivery of drugs for the management of atrial fibrillation. Am J Cardiovasc Drugs. 2023;23(1):1–7. doi: 10.1007/s40256-022-00551-8
   PubMed Web of Science ®Google Scholar
• Ruscica M, Sirtori CR, Carugo S, et al. Omega-3 and cardiovascular prevention – is this still a choice? Pharmacological Research. 2022;182:106342. doi: 10.1016/j.phrs.2022.106342
   PubMed Web of Science ®Google Scholar
• Bays HE. Safety considerations with omega-3 fatty acid therapy. Am J Cardiol. 2007;99(6):S35–S43. doi: 10.1016/j.amjcard.2006.11.020
   Google Scholar
• Harris WS. Expert opinion: omega-3 fatty acids and bleeding-cause for concern? Am J Cardiol. 2007;99(6):S44–S46. doi: 10.1016/j.amjcard.2006.11.021
   Google Scholar
• Sheikh O, Vande Hei AG, Battisha A, et al. Cardiovascular, electrophysiologic, and hematologic effects of omega-3 fatty acids beyond reducing hypertriglyceridemia: as it pertains to the recently published REDUCE-IT trial. Cardiovasc Diabetol. 2019;18(1):84. doi: 10.1186/s12933-019-0887-0
   PubMedGoogle Scholar
• Olshansky B, Bhatt DL, Miller M, et al. Cardiovascular benefits of icosapent ethyl in patients with and without atrial fibrillation in REDUCE-IT. J Am Heart Assoc. 2023;12(5):e26756. doi: 10.1161/JAHA.121.026756
   Web of Science ®Google Scholar
• Kalstad AA, Myhre PL, Laake K, et al. Effects of n-3 fatty acid supplements in elderly patients after myocardial infarction. Circulation. 2021;143(6):528–539. doi: 10.1161/CIRCULATIONAHA.120.052209
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk. JAMA. 2020;324(22):2268. doi: 10.1001/jama.2020.22258
   PubMed Web of Science ®Google Scholar
• Billman GE. The effects of omega-3 polyunsaturated fatty acids on cardiac rhythm: a critical reassessment. Pharmacol Ther. 2013;140(1):53–80. doi: 10.1016/j.pharmthera.2013.05.011
   PubMed Web of Science ®Google Scholar
• Ruscica M, Ferri N, Banach M, et al. Side effects of statins: from pathophysiology and epidemiology to diagnostic and therapeutic implications. Cardiovasc Res. 2023;118(17):3288–3304. doi: 10.1093/cvr/cvac020
   PubMed Web of Science ®Google Scholar
• Bytyci I, Penson PE, Mikhailidis DP, et al. Prevalence of statin intolerance: a meta-analysis. Eur Heart J. 2022;43(34):3213–3223. doi: 10.1093/eurheartj/ehac015
   PubMed Web of Science ®Google Scholar
• Chapman MJ, Zamorano JL, Parhofer KG. Reducing residual cardiovascular risk in Europe: therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid. Pharmacol Ther. 2022;237:108172
   PubMed Web of Science ®Google Scholar